Chronic functional somatic symptoms: a single syndrome?

Tim C olde Hartman, Peter L B J Lucassen, Eloy H van de Lisdonk, Hans H J Bor and Chris van Weel

SUMMARY

Background: Reliable longitudinal data of patients with functional somatic symptoms in general practice are lacking.

Aims: To identify distinctive features in patients with chronic functional somatic symptoms, and to determine whether these symptoms support the hypothesis of the existence of specific somatic syndromes.

Design of study: Observational study, with a comparison control group.

Setting: Four primary care practices affiliated with the University of Nijmegen in the Netherlands.

Method: One hundred and eighty-two patients diagnosed between 1998 and 2002 as having chronic functional somatic symptoms and 182 controls matched by age, sex, socioeconomic status, and practice were included. Data on comorbidity, referrals, diagnostic tests, and hospital admissions over a period of 10 years prior to the diagnosis were collected. Medication use and number of visits to the general practitioner (GP) were extracted from the moment computerised registration was started.

Results: In the 10 years before the diagnosis of chronic functional somatic symptoms, significantly more patients than controls presented functional somatic symptoms in at least two body systems, and used more somatic and psychotropic drugs. They visited the GP twice as much, statistically had significantly more psychiatric morbidity, and were referred more often to mental health workers and somatic specialists. The number of patients undergoing diagnostic tests was higher for patients with chronic functional somatic symptoms than for controls, but hospital admissions rates were equal.

Conclusion: Patients with chronic functional somatic symptoms have a great diversity of functional somatic symptoms. They use more somatic and psychotropic drugs than controls in the years before diagnosis. Moreover, they show high rates of referrals and psychiatric morbidity. The diversity of symptoms of patients with chronic functional somatic symptoms supports the concept that symptoms do not cluster in well defined distinct syndromes. Therefore, patients with chronic functional somatic symptoms should preferably not be classified into medical subspecialty syndromes.

Keywords: somatoform disorders; psychophysiological disorders; family practice; referral and consultation; comorbidity.

Introduction

Medically unexplained symptoms are common, and account for one in five new consultations in primary care. In 25–50% of all primary care visits, no serious medical (that is, organic) cause is found to explain the patient’s presenting symptom, and 20–40% of the patients seen by medical specialists do not receive a clear diagnosis. The presented symptoms are then referred to as ‘medically unexplained’ or ‘functional’. Functional, or rather medically unexplained, somatic symptoms are ranked second on the list of the 10 most common physical symptoms in primary care and have an incidence rate of 70 per 1000 patient years in the Netherlands.

Although an occasional visit to the general practitioner (GP) for a functional somatic symptom seems natural, repeated consultations because of these symptoms represent a serious problem. Patients who do this are often diagnosed as having ‘chronic functional somatic symptoms’. Psychological distress or psychosocial problems are presumed to be the underlying causes. As such, diagnosing chronic functional somatic symptoms requires the patient to repeatedly present physical symptoms that remain medically unexplained after adequate examination, and indications from the patient’s personal circumstances of presumed psychosocial problems or psychological distress. When experiencing functional somatic symptoms seems to have become a regular way of presenting, a patient is registered as having chronic functional somatic symptoms.

As patients with chronic functional somatic symptoms are functionally impaired, have high rates of comorbid psychiatric disorders, and are at risk of unnecessary diagnostic procedures and treatments, a correct diagnosis is of paramount importance. However, most research on this topic has been performed either on unselected population-based samples, or in selected patients referred to secondary care. Moreover, most of these studies make use of questionnaires in which patients have to recall a variety of symptoms existing for a considerable amount of time. This method has been shown to produce unstable results in which lifetime symptoms present at baseline are not remembered at follow-up. Research on patients from primary care settings in whom the diagnosis had been made on reliable longitudinal data is generally lacking.

Moreover, there is considerable debate regarding the question of whether functional somatic symptoms cluster in well-defined distinct syndromes, such as fibromyalgia, chronic fatigue syndrome, or tension headache, or whether these specific somatic syndromes are largely an artefact of medical specification. In this debate reliable data on primary care patients are also needed, whereas most research...
Patients with chronic functional somatic symptoms

We selected all patients from the CMR database in whom chronic functional somatic symptoms were diagnosed for the first time between 1998 and 2002 (n = 182). For a period of 10 years before this diagnosis, the following variables had been collected: sociodemographic characteristics; morbidity data; and data on referrals, diagnostic tests, and hospital admissions. Use of medical facilities was assessed by the number of contacts with the GP. Data on medication use could be extracted from when computerised registration started, and medication data were transformed into the prescribed daily dose by using the Anatomical Therapeutical Chemical Classification/Defined Daily Doses (ATC/DDD) system. As a proxy of somatic morbidity, we assessed three prevalent categories of chronic disorders (diabetes mellitus, asthma/chronic obstructive pulmonary disease [COPD], and cardiovascular diseases) and three prevalent categories of self-limiting disorders (skin, musculoskeletal, and airway) in order to study the hypothesis that patients with chronic functional somatic symptoms are at risk of somatic morbidity.

We allocated the registered functional somatic symptoms to specific body systems; for example, gastrointestinal or musculoskeletal, as described by Escobar et al. Irritable bowel syndrome and hyperventilation syndrome, sometimes regarded as medically unexplained symptoms, are not included in this study.

Controls

For each patient with chronic functional symptoms, a control matched by age, sex, socioeconomic status, and practice was drawn from the CMR population. The only exclusion criterion in the control group was the diagnosis of chronic functional somatic symptoms. Patients who were controls had to have had at least one registered episode of illness during the period they had been on the practice list. For controls, the same information as described for patients with chronic functional somatic symptoms was obtained from 1990–2000.

Statistical methods

Our analysis primarily involved comparing patients with chronic functional somatic symptoms with their matched controls. Statistical analyses were conducted using SPSS 9.0. Descriptive statistics were calculated for all variables. The data on specific body systems were analysed using exploratory factor analysis, and then simplified by varimax rotation. The $\chi^2$ test and student’s t-test were used for comparing means of consultations and medication use in both groups. Odds ratios (ORs) and 95% confidence intervals (CIs) were used as the main measurement for associations, particularly with regard to functional somatic symptoms, comorbidity, referrals, diagnostic tests, and hospital admissions. All $P$-values are two-tailed.

Results

Characteristics of subjects

Of the 182 patients with chronic functional somatic symptoms included in the study, 141 (77.5%) were women; the
mean age of all patients was 42.0 years (range = 10–85 years). Most subjects were of low (44.5%) or middle (42.9%) socioeconomic class.

Functional somatic symptoms
The incidence rate of patients with chronic functional somatic symptoms was 3.5 per 1000 patient years, whereas the prevalence of patients known to have chronic functional somatic symptoms is established on 68.8 per 1000 patient years.

The presented functional somatic symptoms in various body systems in patients and controls is displayed in Table 1. For each symptom group, patients and controls differ significantly ($P < 0.05$). It is remarkable that many patients had symptoms in various body systems — a finding that is supported by the factor analysis (Figure 1) — as it is often considered that there are a number of well-defined distinct functional somatic syndromes, clustering around physical symptoms of one body system. Moreover, factor analysis suggests that, on the one hand, gastrointestinal, cardiorespiratory, and pseudopsychiatric symptoms are linked and, on the other, that pseudoneurological symptoms, musculoskeletal symptoms, and headache and other pain, are linked with each other. Significantly more patients than controls presented symptoms in two or more body systems (87.9% versus 19.8%; $OR = 29.5$, 95% CI = 16.0 to 54.9). Of all the patients, 25% presented symptoms in four or more body systems.

Half of the patients had three or more episodes of functional somatic symptoms before he or she was diagnosed as having chronic functional somatic symptoms; 25% of patients had five or more episodes before chronic functional somatic symptoms were diagnosed.

Comorbidity: somatic and psychiatric
Patients with chronic functional somatic symptoms had significantly more psychiatric disorders in comparison with controls ($OR = 2.4$) (Table 2). Patients did not have a much higher rate of chronic and self-limiting somatic comorbidity, and they had only slightly more episodes of self-limiting airway problems than controls.

Consultations, referrals, diagnostic tests and hospital admissions
The number of consultations in patients with chronic functional somatic symptoms is significantly higher ($n = 9.8$ versus $n = 4.2, P<0.001$), as is the number of subjects referred for diagnostic testing ($n = 156$ versus $n = 140, OR = 1.8$). The number of home visits was equal in both groups. About three-quarters of patients had been referred to somatic specialists, compared with about half of the controls. About one-third of the patients had been referred to mental health sources compared with less than 10% in controls. Hospital admissions were the same. These data are outlined in Table 2.

Medication use
The results regarding medication use are detailed in Table 3. We found that patients with chronic functional somatic symptoms used significantly more somatic medications (2.6 versus 1.5, $P<0.001$) and psychotropic drugs (0.4 versus 0.05, $P<0.001$) per year compared with controls. The number of patients using antidepressants and benzodiazepines is statistically different in both groups (35.6% versus 5.9%; 52.5% versus 12.7% respectively, $P<0.001$).

Figure 1. Symptom diversity in patients with chronic functional somatic symptoms and their matched controls.
Table 2. Number of consultations, comorbidity, referrals, diagnostic tests, and hospital admissions in patients and controls (n = 182).

<table>
<thead>
<tr>
<th></th>
<th>Patients</th>
<th>Controls</th>
<th>P-value</th>
<th>Odds ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GP consultations in 1 year (mean [range])</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Practice visits</td>
<td>9.8 (2.5–26.8)</td>
<td>4.2 (0–15.1)</td>
<td>&lt;0.001</td>
<td>-</td>
</tr>
<tr>
<td>Home visits</td>
<td>0.2 (0–3.5)</td>
<td>0.3 (0–7.1)</td>
<td>0.53</td>
<td>-</td>
</tr>
<tr>
<td>Comorbidity (n [%])</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Somatic chronic:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>5 (2.7)</td>
<td>4 (2.2)</td>
<td>-</td>
<td>1.3 (0.3 to 5.7)</td>
</tr>
<tr>
<td>Asthma/COPD</td>
<td>20 (11.0)</td>
<td>10 (5.5)</td>
<td>-</td>
<td>2.1 (0.9 to 5.0)</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>16 (8.8)</td>
<td>8 (4.4)</td>
<td>-</td>
<td>2.1 (0.8 to 5.5)</td>
</tr>
<tr>
<td>Somatic self-limiting</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin</td>
<td>96 (52.7)</td>
<td>82 (45.1)</td>
<td>-</td>
<td>1.4 (0.9 to 2.1)</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>130 (71.4)</td>
<td>115 (63.2)</td>
<td>-</td>
<td>1.5 (0.9 to 2.3)</td>
</tr>
<tr>
<td>Airway</td>
<td>136 (74.4)</td>
<td>113 (62.1)</td>
<td>-</td>
<td>1.8 (1.1 to 2.9)</td>
</tr>
<tr>
<td>Psychiatricc</td>
<td>41 (22.5)</td>
<td>20 (11.0)</td>
<td>-</td>
<td>2.4 (1.3 to 4.4)</td>
</tr>
<tr>
<td>Referrals (n [%])</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Somatic: medical</td>
<td>130 (71.4)</td>
<td>97 (53.3)</td>
<td>-</td>
<td>2.2 (1.4 to 3.5)</td>
</tr>
<tr>
<td>Somatic: paramedicald</td>
<td>129 (70.9)</td>
<td>87 (47.8)</td>
<td>-</td>
<td>2.6 (1.7 to 4.2)</td>
</tr>
<tr>
<td>Mental health</td>
<td>59 (32.4)</td>
<td>15 (8.2)</td>
<td>-</td>
<td>5.3 (2.9 to 10.3)</td>
</tr>
<tr>
<td>Diagnostic testd (n [%])</td>
<td>156 (85.7)</td>
<td>140 (76.9)</td>
<td>-</td>
<td>1.8 (1.0 to 3.2)</td>
</tr>
<tr>
<td>Hospital admissions (n [%])</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Somatic</td>
<td>57 (31.3)</td>
<td>51 (28.0)</td>
<td>-</td>
<td>1.2 (0.7 to 1.9)</td>
</tr>
<tr>
<td>Psychiatric</td>
<td>1 (0.5)</td>
<td>1 (0.5)</td>
<td>-</td>
<td>1.0</td>
</tr>
</tbody>
</table>

*4 n = 118: one general practice did not use the computerised registration, so consultation could not be established in this practice. *5Statistically significant difference between patients and controls P < 0.05. *6Including schizophrenia, depression, psychoses, hysteria, phobia, neuroses, post-traumatic stress disorder, alcoholism, use of street drugs. *7Including physiotherapist, dietician. *8Including haematological tests, x-ray examinations, ultrasonography, and electrocardiography.

In patients using medication, antidepressants were used for a mean of 20 days a year and benzodiazepines for 9 days a year compared with 5 and 4 days, respectively, in controls. However, these findings do not reach statistical significance. Moreover, there is no difference in prescribed daily dose for patients and controls.

Discussion

Strengths and limitations of this study

The strength of the present study is that the patients who were included were those who consulted their GP, irrespective of the presented symptoms. Therefore, a threshold of relevance of the symptoms for the patient was established and we were able to analyse all symptoms presented. Most population-based studies assess all symptoms irrespective of the perceived need for help. Moreover, in population-based studies, interviewing patients repeatedly does not lead to a consistent classification of somatoform disorders, whereas our classification of the presented morbidity is based on very stable data, in which longitudinal research is allowed and recall bias will not occur.

The limitations of the study are the retrospective use of data in existing medical records and the possible interdoctor variation of the diagnosis of chronic functional somatic symptoms. The interdoctor variation is partly a consequence of not having explicitly stated criteria for chronic functional somatic symptoms in the CMR. This subjectivity will possibly always exist because diagnosing chronic functional somatic symptoms remains an interpretation of the symptoms, and is influenced by foreknowledge and context. However, it is known from the literature that the GP’s judgement on somatisation seems valid in daily practice. Moreover, additional validation of clinical judgement is possible through longitudinal follow-up. The subjectivity of the diagnosis and the doctor–patient relationship also make important contributions to the genesis and persistence of functional somatic symptoms. The doctor’s knowledge of the patient’s complaints is an important issue and is associated with a better outcome.

Of all the variables described, only consultation frequency is directly linked with the diagnosis of chronic functional somatic symptoms — as such, the higher frequency of GP visits was to be expected a priori.

Summary of main findings

This is the first observational study using longitudinal data describing patients in whom consulting the GP for functional somatic symptoms has become a regular way of presenting. During the 10 years before a diagnosis of chronic functional somatic symptoms is established by the GP, patients consult their GP twice as much, use much more somatic and psychotropic medication, have more psychiatric morbidity and are more often referred to mental health workers than controls. During these 10 years, the number of diagnostic tests is slightly higher in patients and the number of hospital admissions is equal in comparison with controls. Patients with chronic functional somatic symptoms are more likely to present symptoms in two or more body systems and they present a higher number and greater diversity of symptoms to the GP than control.
Table 3. Medication use in patients and controls (n = 118).

<table>
<thead>
<tr>
<th></th>
<th>Patients</th>
<th>Controls</th>
<th>P-value</th>
<th>Odds ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of somatic medications per year (mean [range])</td>
<td>2.6 (0–18.0)</td>
<td>1.5 (0–7.5)</td>
<td>&lt;0.001a</td>
<td>-</td>
</tr>
<tr>
<td>Number of psychotropic drugs per year (mean [range])</td>
<td>0.4 (0–9.0)</td>
<td>0.05 (0–0.62)</td>
<td>&lt;0.001</td>
<td>-</td>
</tr>
<tr>
<td>Number of patients using psychotropic drugs (n [%])</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antidepressants</td>
<td>42 (35.6)</td>
<td>7 (5.9)</td>
<td>-</td>
<td>7.5 (3.1 to 18.9)</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>62 (52.5)</td>
<td>15 (12.7)</td>
<td>-</td>
<td>5.8 (3.0 to 11.1)</td>
</tr>
<tr>
<td>Others</td>
<td>3 (2.5)</td>
<td>3 (2.5)</td>
<td>-</td>
<td>1.0</td>
</tr>
<tr>
<td>Days of psychotropic drug use per year (median [range])</td>
<td>19.5 (1.9–297.0)c</td>
<td>5.0 (1.62–91.7)d</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>8.9 (0.4–322.5)c</td>
<td>4.2 (1.1–90.8)d</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>34.3 (1.7–58.2)c</td>
<td>3.8 (0.2–25.1)d</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Prescribed daily doses (mean [range])</td>
<td>0.76 (0.20–1.37)c</td>
<td>0.77 (0.13–2.00)d</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>0.62 (0.06–1.50)c</td>
<td>0.61 (0.20–1.54)d</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>0.62 (0.25–0.75)</td>
<td>0.31 (0.25–0.40)d</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>


n = 118: one general practice did not use the computerised registration, so medication could not be established in this practice. aStatistically significant difference between patients and controls P <0.05. bFor patients with antidepressants, benzodiazepines and other psychotropic drugs, n = 42, 62, and 3, respectively. cFor patients with antidepressants, benzodiazepines and other psychotropic drugs, n = 7, 15, and 3, respectively.

patients. GPs in this study appear to classify patients as having chronic functional somatic symptoms after three episodes of presenting with functional somatic symptoms.

Comparison with the existing literature

The finding that patients could be recognised as having chronic functional somatic symptoms after they had experienced three episodes of functional somatic symptoms presented in two or more body systems, is an important one. Functional somatic symptoms are often recognised after having excluded other possible diagnoses. This may be associated with unnecessary and possibly harmful diagnostic strategies and may promote somatic fixation. Early identification of these patients could prevent somatic fixation, and enables the GP to modify his/her proceedings.39 Additionally, this finding was confirmed using factor analysis and shows that functional somatic symptoms probably do not cluster in well defined specific somatic syndromes. It also suggests that symptom variation is great in these patients.

The concept of patients with functional somatic syndromes presenting symptoms in many body systems has also been supported by recent studies.20 Therefore, the existence of specific somatic syndromes should be challenged. With a broad-based approach, the GP might be the appropriate practitioner to diagnose and treat these patients by emphasising the biomedical as well as the psychosocial factors involved in symptom production and perception.40

The finding that patients with chronic functional somatic symptoms did not have a higher rate of chronic and self-limiting somatic comorbidity is remarkable because it is stated in the literature that somatisation with more frequent examination may increase the chance of chronic diseases being discovered.36 We found that more frequent consultation did not lead to more diagnosed chronic and self-limiting diseases in patients with chronic functional somatic symptoms.

The diagnosis of chronic functional somatic symptoms is not recorded as such in the DSM-IV classification. It no doubt exists as part of the spectrum somewhere between somatisation disorder and somatoform disorder not otherwise specified. The condition resembles the concept of ‘abridged somatisation’,10 but is not based on the number of symptoms. Both ‘abridged somatisation’ and chronic functional somatic symptoms presume underlying psychological distress. The prevalence of somatisation disorder according to the DSM-IV in primary care is low because of the stringent criteria.40,41 On the other hand, less severe forms of somatisation have a major impact on quality of life and on the use of health services, and are more prevalent.

Implications for further research and clinical practice

Patients with chronic functional somatic symptoms may be considered as persistent complainers and consequently labelled as ‘difficult’ patients. The condition may indeed reflect a greater propensity to complain; however, as is apparent from the excess of psychiatric comorbidity, patients with chronic functional somatic symptoms also have more reason to complain. With regard to these patients, it seems that consulting the GP for functional somatic symptoms has become a regular way of presenting, but it might also be that patients who attend more often are at higher risk of being considered as having chronic functional somatic symptoms. Moreover, the diagnosis might relate to frustrated doctors as a consequence of lack of understanding, or failures in the communication between doctor and patient.

Chronic functional somatic symptoms are a major cause of morbidity and deserve further investigation to estimate the importance of the doctor–patient relationship, the feasibility of treatments, and the understanding of the aetiology of functional symptoms to identify patients who are likely to become persistent complainers.
and develop the behavioural pattern of patients with chronic functional somatic symptoms. Also, the overlap of chronic functional somatic symptoms with the various DSM-IV diagnoses should be studied. This is important because the validity of the classification of mental disorders is useful, but also questionable.22 Thinking in narrow syndromes might hinder an appropriate interpretation of the patient’s syndromes.

Patients repeatedly presenting functional somatic symptoms to the GP in two or more body systems, particularly when combined with psychological complaints, should be regarded as candidates for the diagnosis of chronic functional somatic symptoms. It seems that the presented functional somatic symptoms are part of a single syndrome and that symptom variation is great in these patients. Therefore, the GP, who is considered as being knowledgeable about underlying psychosocial problems, should diagnose, treat, and accompany these patients.

References


Acknowledgements

We are grateful to the GPs and practice nurses for being able to carry out our research work in their CMR practices, and we would like also to thank Ank de Jonge and Vivien Moffat for reviewing the manuscript.